Durgesh Pagar
Research Subjects
Durgesh Pagar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chandrashekhar Dinkar Patil
Department of Pharmacology, Divine College of Pharmacy, Satana, Nashik, Maharashtra, 423301, India
2 shared publications - Deepak B. Somavanshi1 shared publication
- Durgesh T. Gautam1 shared publication
- Ganesh Sonawane
Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, India
1 shared publication - Jubershaha S. Fakir
Department of Pharmacology, Shri Shakti Shaikshanik Sanstha Divine College Pharmacy, Satana, Maharashtra, 423301, India
1 shared publication - Kajal Pansare
Department of Pharmacology, Savitribai Phule Pune University Affiliated, KBHSS Trusts Institute of Pharmacy, Malegaon, Nashik, India
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 2141-2151
Investigation of the Antioxidant Signalling Mechanisms of Rosmarinus officinalis L. in an Aniline-induced Splenic Toxicity Rat Model
Background: Aniline is an industrial chemical whose reactive metabolites induce oxidative stress and structural damage in splenic tissue, making aniline-induced splenic toxicity in rats a well-established experimental model for evaluating protective interventions. Rosmarinus officinalis L. (rosemary) possesses potent antioxidant and anti-inflammatory phytochemicals that may mitigate chemically induced tissue injury. Aim: To investigate the antioxidant-mediated splenoprotective effects of Ethanolic Rosemary Extract (ERE) against aniline-induced splenic toxicity in male Wistar rats. Methods: Male Wistar rats (200-250 g) were randomly divided into five groups (n = 6) and treated for 30 days. Splenic toxicity was induced by oral administration of aniline hydrochloride (50 mg/kg/day). Protective treatment groups received ERE at doses of 100 or 200 mg/kg/day orally, while citric acid (100 mg/kg/day, p.o.) served as the reference standard. Physiological parameters, oxidative stress biomarkers, antioxidant enzyme activities (GSH and CAT), ATPase activity, serum biochemical indices, histopathological changes, and hemosiderin deposition were assessed. Statistical analysis was performed using one-way ANOVA, with p<0.05 considered statistically significant. Results: Aniline administration produced splenomegaly, excessive iron accumulation, elevated lipid peroxidation, impaired antioxidant defences, reduced ATPase activity, and pronounced histopathological alterations including fibrosis and disruption of normal splenic architecture. Treatment with ERE significantly ameliorated these toxic effects in a dose-dependent manner. Rosemary extract restored antioxidant enzyme levels, reduced lipid peroxidation and nitric oxide production, improved ATPase activity, decreased hemosiderin deposition, normalised haematological and biochemical parameters, and preserved splenic histoarchitecture. The higher dose (200 mg/kg) demonstrated the greatest protective efficacy. Conclusion: ERE effectively protects against aniline-induced splenic toxicity by attenuating oxidative stress, restoring antioxidant defences, reducing iron accumulation, and preserving tissue architecture, suggesting its potential as a natural splenoprotective agent. Major Findings: ERE significantly ameliorated oxidative stress, restored antioxidant enzyme activity, improved haematological indices, reduced splenic iron overload, and preserved splenic histoarchitecture, with the 200 mg/kg dose producing the greatest protective effect.
- 31 August 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 2141-2151
Open AccessInvestigation of the Antioxidant Signalling Mechanisms of Rosmarinus officinalis L. in an Aniline-induced Splenic Toxicity Rat Model
Background: Aniline is an industrial chemical whose reactive metabolites induce oxidative stress and structural damage in splenic tissue, making aniline-induced splenic toxicity in rats a well-established experimental model for evaluating protective interventions. Rosmarinus officinalis L. (rosemary) possesses potent antioxidant and anti-inflammatory phytochemicals that may mitigate chemically induced tissue injury. Aim: To investigate the antioxidant-mediated splenoprotective effects of Ethanolic Rosemary Extract (ERE) against aniline-induced splenic toxicity in male Wistar rats. Methods: Male Wistar rats (200-250 g) were randomly divided into five groups (n = 6) and treated for 30 days. Splenic toxicity was induced by oral administration of aniline hydrochloride (50 mg/kg/day). Protective treatment groups received ERE at doses of 100 or 200 mg/kg/day orally, while citric acid (100 mg/kg/day, p.o.) served as the reference standard. Physiological parameters, oxidative stress biomarkers, antioxidant enzyme activities (GSH and CAT), ATPase activity, serum biochemical indices, histopathological changes, and hemosiderin deposition were assessed. Statistical analysis was performed using one-way ANOVA, with p<0.05 considered statistically significant. Results: Aniline administration produced splenomegaly, excessive iron accumulation, elevated lipid peroxidation, impaired antioxidant defences, reduced ATPase activity, and pronounced histopathological alterations including fibrosis and disruption of normal splenic architecture. Treatment with ERE significantly ameliorated these toxic effects in a dose-dependent manner. Rosemary extract restored antioxidant enzyme levels, reduced lipid peroxidation and nitric oxide production, improved ATPase activity, decreased hemosiderin deposition, normalised haematological and biochemical parameters, and preserved splenic histoarchitecture. The higher dose (200 mg/kg) demonstrated the greatest protective efficacy. Conclusion: ERE effectively protects against aniline-induced splenic toxicity by attenuating oxidative stress, restoring antioxidant defences, reducing iron accumulation, and preserving tissue architecture, suggesting its potential as a natural splenoprotective agent. Major Findings: ERE significantly ameliorated oxidative stress, restored antioxidant enzyme activity, improved haematological indices, reduced splenic iron overload, and preserved splenic histoarchitecture, with the 200 mg/kg dose producing the greatest protective effect.
- Open Access
- 30 December 2025
- Published by Quality Academic And Scientific Publishing Agency (QAASPA Publisher) in BioMed Target Journal
- Vol. 3 (2) , 18-28
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Worldwide prevalence of type 2 diabetes mellitus (T2DM) and obesity has heightened the need to find treatments that control hyperglycemia, together with weight gain and resultant organ damage. Under this arrangement, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents. They act through both intra- and extrapancreatic pathways to promote glucose-dependent insulin secretion, lower glucagon concentrations, slow stomach emptying, and control circuits of cerebral appetite. This helps the body regulate blood glucose levels, leading to clinically significant weight loss. In addition to regulating metabolism, strong cardiovascular and renal outcome trial data (including STEP, SELECT, and FLOW) suggest that they can lower the disease burden of serious cardiovascular events and protect kidney functioning. It means they are disease-modifying agents. Other barriers include their high cost, gastrointestinal side effects, injectable formulations, and lack of long-term safety information, although they are an effective intervention for achieving greater use. Recently, novel agents such as oral semaglutide, dual and triple incretin agonists (tirzepatide, retatrutide), and drug-based combinations with sodium-glucose cotransporter-2 (SGLT2) have revolutionized the treatment of the disease and improved its clinical utility. Individualized optimization of treatment using precision medicine, in the form of tailored behavior, with respect to phenotypes and comorbidities, holds promise to enhance outcomes. The combination of glycemic control, long-term weight loss, and organ protection is shifting the approach to cardiac, renal, and other organ health, leveraging the action of GLP-1 receptor agonists.
- 30 December 2025
- Published by Quality Academic And Scientific Publishing Agency (QAASPA Publisher) in BioMed Target Journal
- Vol. 3 (2) , 18-28
Open AccessGLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Worldwide prevalence of type 2 diabetes mellitus (T2DM) and obesity has heightened the need to find treatments that control hyperglycemia, together with weight gain and resultant organ damage. Under this arrangement, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents. They act through both intra- and extrapancreatic pathways to promote glucose-dependent insulin secretion, lower glucagon concentrations, slow stomach emptying, and control circuits of cerebral appetite. This helps the body regulate blood glucose levels, leading to clinically significant weight loss. In addition to regulating metabolism, strong cardiovascular and renal outcome trial data (including STEP, SELECT, and FLOW) suggest that they can lower the disease burden of serious cardiovascular events and protect kidney functioning. It means they are disease-modifying agents. Other barriers include their high cost, gastrointestinal side effects, injectable formulations, and lack of long-term safety information, although they are an effective intervention for achieving greater use. Recently, novel agents such as oral semaglutide, dual and triple incretin agonists (tirzepatide, retatrutide), and drug-based combinations with sodium-glucose cotransporter-2 (SGLT2) have revolutionized the treatment of the disease and improved its clinical utility. Individualized optimization of treatment using precision medicine, in the form of tailored behavior, with respect to phenotypes and comorbidities, holds promise to enhance outcomes. The combination of glycemic control, long-term weight loss, and organ protection is shifting the approach to cardiac, renal, and other organ health, leveraging the action of GLP-1 receptor agonists.